CV Sciences, Inc. (CVSI): Operating Cash Flow
-$407.0K
Year ended 2025-12-31
-$492.0K
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$407.0K | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$861.0K | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $2.25M | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$1.89M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$7.49M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$7.30M | n/m | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | -$2.23M | n/m | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $12.56M | +247.4% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $3.62M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$2.05M | n/m | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | -$4.21M | n/m | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | -$6.71M | n/m | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | -$4.88M | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$64.1K | n/m | 2013-04-16, From 2012-01-01 |
| 2011-12-31 | -$79.6K | n/a | 2013-04-16, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$407.0K | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$63.50M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$39.64M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$35.25M | n/m |
| Palatin Technologies Inc (PTN) | 2026-06-30 | -$13.53M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$99.84M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$76.44M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$11.0K | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$56.30M | n/m |
Compare CVSI, PYXS, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗